EYEN Eyenovia Inc

Price (delayed)

$1.39

Market cap

$74.88M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.73

Enterprise value

$83.54M

Eyenovia, Inc. is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for ...

Highlights
EYEN's gross profit has surged by 132% since the previous quarter
The revenue has soared by 132% since the previous quarter
The company's equity has shrunk by 89% YoY and by 80% QoQ
The company's quick ratio has shrunk by 88% YoY and by 69% QoQ

Key stats

What are the main financial stats of EYEN
Market
Shares outstanding
53.87M
Market cap
$74.88M
Enterprise value
$83.54M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
36.24
Price to sales (P/S)
7,378.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9,514.62
Earnings
Revenue
$8,780
EBIT
-$29.85M
EBITDA
-$29.01M
Free cash flow
-$30.02M
Per share
EPS
-$0.73
Free cash flow per share
-$0.64
Book value per share
$0.04
Revenue per share
$0
TBVPS
$0.43
Balance sheet
Total assets
$26.18M
Total liabilities
$24.36M
Debt
$16.63M
Equity
$1.82M
Working capital
-$2.01M
Liquidity
Debt to equity
9.15
Current ratio
0.88
Quick ratio
0.49
Net debt/EBITDA
-0.3
Margins
EBITDA margin
-330,448.9%
Gross margin
200%
Net margin
-369,519.7%
Operating margin
-343,927.9%
Efficiency
Return on assets
-108.9%
Return on equity
-349.6%
Return on invested capital
-157%
Return on capital employed
-307.2%
Return on sales
-339,946.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EYEN stock price

How has the Eyenovia stock price performed over time
Intraday
15.83%
1 week
18.8%
1 month
113.85%
1 year
-37.67%
YTD
-33.17%
QTD
135.59%

Financial performance

How have Eyenovia's revenue and profit performed over time
Revenue
$8,780
Gross profit
$17,560
Operating income
-$30.2M
Net income
-$32.44M
Gross margin
200%
Net margin
-369,519.7%
EYEN's gross profit has surged by 132% since the previous quarter
The revenue has soared by 132% since the previous quarter
The operating margin rose by 49% QoQ
Eyenovia's net margin has increased by 49% from the previous quarter

Growth

What is Eyenovia's growth rate over time

Valuation

What is Eyenovia stock price valuation
P/E
N/A
P/B
36.24
P/S
7,378.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9,514.62
The EPS has contracted by 11% from the previous quarter
EYEN's P/B is 159% above its last 4 quarters average of 12.1
The company's equity has shrunk by 89% YoY and by 80% QoQ
The revenue has soared by 132% since the previous quarter

Efficiency

How efficient is Eyenovia business performance
The ROE has shrunk by 155% YoY and by 64% QoQ
The ROS has grown by 48% from the previous quarter
Eyenovia's ROIC has increased by 45% YoY but it has decreased by 27% from the previous quarter
Eyenovia's ROA has decreased by 31% YoY and by 22% from the previous quarter

Dividends

What is EYEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EYEN.

Financial health

How did Eyenovia financials performed over time
The total assets is 7% greater than the total liabilities
The company's quick ratio has shrunk by 88% YoY and by 69% QoQ
Eyenovia's current ratio has plunged by 83% YoY and by 59% from the previous quarter
The company's equity has shrunk by 89% YoY and by 80% QoQ
Eyenovia's debt has soared by 51% YoY and by 3.4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.